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18F-2-deoxy-2-fluoro-glucose Positron Emission Tomography (FDG-PET) has been recently proposed as a promising cancer-
screening test. However, the validity of FDG-PET in cancer screening has not been evaluated. We investigated the sensitivity of FDG-
PET compared with upper gastric endoscopy in gastric cancer screening for asymptomatic individuals. A total of 2861 consecutive
subjects (1600 men and 1261 women) who were asymptomatic and who underwent both FDG-PET and upper gastrointestinal
endoscopy between 1 February 2004 and 31 January 2005 were included in this study. Both endoscopists and a radiologist were
unaware of the results of the other diagnostic tests. The FDG-PET images were examined using criteria determined by the pattern of
FDG accumulation. Sensitivity and specificity of FDG-PET were calculated compared with endoscopic diagnosis as the gold standard.
Among 2861 subjects enrolled in the study, there were 20 subjects with gastric cancer, of whom 18 were T1 in depth of cancer
invasion. Positive FDG-PET results were obtained only in 2 of the 20 cancer subjects. The calculated sensitivity and specificity
for overall gastric cancers were 10.0% (95% confidence interval (CI): 1.2–31.7%) and 99.2% (95% CI: 98.8–99.5%), respectively.
18F-2-deoxy-2-fluoro-glucose Positron Emission Tomography was poorly sensitive for detection of gastric cancer in the early stages.
British Journal of Cancer (2007) 97, 1493–1498. doi:10.1038/sj.bjc.6604062 www.bjcancer.com
Published online 27 November 2007
& 2007 Cancer Research UK
Keywords: gastric cancer; screening; endoscopy; FDG-PET; sensitivity
                                                 
18F-2-deoxy-2-fluoro-glucose Positron Emission Tomography
(FDG-PET) is a technique that reflects the changes in glucose
metabolism in tumour cells, and has been widely used clinically to
differentiate between benign and malignant tumours (Rigo et al,
1996), to assess the effectiveness of chemotherapy or radiotherapy
(Kelloff et al, 2005), and to predict prognosis (Oshida et al, 1998;
Oku et al, 2002). The potential of FDG-PET for early detection of
cancer has been investigated because the test enables scanning of
the whole body simultaneously and non-invasively. Because of this
advantage, there has been considerable enthusiasm for PET
screening in Japan (Yasuda and Ide, 2005). About 60% of facilities
in Japan that are equipped with PET offer PET examinations to
individuals who hope to undergo cancer screening (Yasuda and
Ide, 2005).
Gastric cancer is one of the most important cancers in terms of
anticancer strategy because it ranks second in cancer mortality in
Japan (World Health Organization Statistics, 2006). There are
many other countries with patients at high risk for gastric cancer,
such as those in Central and South America, Asia, and Eastern
Europe. Although gastric cancer has decreased in most of the
developed countries, its prevention remains an important issue
in those countries. For early detection of gastric cancer, X-ray
examination with a barium meal has been employed in Japan
(Fukao et al, 1995). Efficacy of this kind of screening program has
been strongly suggested, although the studies are observational
(Oshima et al, 1986; Fukao et al, 1995; Mizoue et al, 2003). The
problem with the program is that the screening test is somewhat
invasive in terms of complications such as constipation being
frequently seen and mis-swallowing of barium into the trachea
(Tamura et al, 1985; Sugahara et al, 1992). On the other hand, with
FDG-PET, there is almost no such inconvenience for screenees.
For these reasons, FDG-PET has been explored as a potential
alternative to the present screening test for gastric cancer in Japan.
However, the validity of FDG-PET in cancer screening remains to
be evaluated. Although the sensitivity of FDG-PET for gastric
cancer is reported to be from 60 to 94%, most subjects evaluated in
existing reports were limited to patients with advanced gastric
cancers or recurrent cancers (Yeung et al, 1998; De Potter et al,
2002; Stahl et al, 2003; Yoshioka et al, 2003; Mochiki et al, 2004;
Chen et al, 2005; Yun et al, 2005). There has been no study to
measure screening sensitivity of FDG-PET for gastric cancer in
average risk individuals. Therefore, in the present study, we
investigated the sensitivity of FDG-PET for gastric cancer in
asymptomatic individuals who underwent FDG-PET as well as
screening upper gastrointestinal endoscopy, which served as the
gold standard in calculating the sensitivity of FDG-PET.
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sMATERIALS AND METHODS
Subjects and study design
The Research Center for Cancer Prevention and Screening
(RCCPS), National Cancer Center (NCC), Tokyo, started the one-
arm prospective cohort study designed to evaluate the efficacy of
multiphasic cancer screening programs in 1 February 2004
(Hamashima et al, 2006). Details of the screening programs are
described elsewhere (Hamashima et al, 2006). The screening
programs consisted of upper and lower gastrointestinal endoscopy
or X-ray examinations and other imaging modalities such as a
chest helical CT examination. These examinations were performed
during the 2-day course of the screening program. Individuals who
were found to have cancer lesions were treated at the National
Cancer Center Hospital. Participants were enrolled nationwide.
Screenees were asymptomatic men 50 years or over and women 40
years or over who gave signed informed consent approved by the
Ethics Committee for Clinical Research of the NCC. Subjects who
were diagnosed as having any cancer within the past 1 year, or
those who had been treated for cancer or followed-up for pre-
cancerous diseases based on self-reporting were excluded. All
participants responded to a questionnaire describing many issues
concerning life style, family history, and previous examinations
within a year (Hamashima et al, 2006). Individuals were to be
followed up annually by a questionnaire on health status,
diagnostic examinations (including results), and other relevant
data.
The study population in the present study was defined as
consecutive screenees who underwent both FDG-PET and gastro-
intestinal endoscopy between 1 February 2004 and 31 January 2005
within the screening program at the RCCPS. There were a total of
2911 individuals who underwent FDG-PET, among whom 2892
individuals, including 1626 men and 1266 women, also had gastric
endoscopy and thus met the criteria for inclusion. Thirty-one
individuals were excluded who had undergone gastrectomy.
After excluding these subjects, the study population of 2861
participants, including 1600 men and 1261 women, was included in
the analyses.
The endoscopic findings and images were examined by three
skilled endoscopists (HS, YK, and TK) without any knowledge of
FDG-PET findings. The FDG-PET images were examined by one
expert radiologist specialising in nuclear medicine (TT), who had
no information about the endoscopic findings. Findings and
diagnoses were recorded separately by endoscopists and the
radiologist on the electronic record system at the RCCPS to create
the database of the participants. After the records were completed,
findings from the two modalities were compared by either of the
two investigators (HS and YM) to identify true positives and false
negatives from FDG-PET results for gastric cancer based on
endoscopic findings as the gold standard. Gastric cancer subjects
were defined as those who were diagnosed as having gastric cancer
at the time of screening or on additional endoscopy performed
within 1 month after the screening.
The study protocol was approved by the Ethics Committee for
Clinical Research of the NCC.
Information on cancers other than gastric cancers detected in
the background population from which the present study
population was drawn was described previously (Hamashima
et al, 2006).
18F-2-deoxy-2-fluoro-glucose Positron Emission
Tomography procedure
The FDG-PET images were obtained using two multi-ring PET
scanners (ECAT Accel, Siemens, Knoxville, TN, USA) with a
transaxial resolution of 6.2mm at full-width half-maximum.
Subjects were required to fast for at least 5h before the PET scan.
Sixty minutes after injection of 2.78MBqkg
 1 of FDG that was
produced in our radiopharmacy, emission and transmission scans
were obtained from the head to the inguinal region. A three-
dimensional emission scan was acquired in eight or nine bed
positions for 2min per position, followed by a two-dimensional
transmission scan for 1min per position to correct for photon
attenuation using a 68Ge/Ga rod source. Images were recon-
structed iteratively (ordered-subset expectation maximisation
method, two iterations, eight subsets).
The standardised uptake value (SUV) was semiquantitated in
the cases with uptakes suspected of being abnormal. The SUV can
be calculated as the ratio of the FDG uptake in a small region of
interest (placed over the lesion in an attenuation-corrected image)
to the administered activity adjusted for the body weight of the
patient (Bombardieri et al, 2003).
Assessment of FDG-PET findings
Criteria for the assessment of FDG-PET findings for gastric lesions
vary among facilities despite the widespread use of the guidelines
for the FDG-PET procedure, mainly due to the difficulties caused
by physiological uptake in the stomach. Because there are no
established criteria for assessing FDG-PET findings, we determined
the following criteria based on previous reports (Cook et al, 1996;
Gordon et al, 1997; Shreve et al, 1999; Koga et al, 2003): (1)
positive pattern 1 – spotty or focal accumulation that was stronger
than the uptake in the liver (Figure 1A); positive pattern 2 – any
accumulation in the area of the lower stomach (Figure 1B). This
category was based on a report by Koga et al (2003), suggesting
that physiological gastric FDG uptake is significantly higher at the
oral end than the anal end, and that a stronger gastric FDG uptake
at the anal end might therefore be suggestive of a pathological
uptake. (2) negative pattern 1 – no definite accumulation in the
stomach (Figure 1C); negative pattern 2 – diffuse accumulation in
the stomach, considered to be a normal physiological uptake
(Figure 1D). The judgment of FDG-PET accumulation was made
based only on PET without CT scan. Positive whole body FDG-PET
findings were obtained in 9% of 2911 subjects who had FDG-PET
examinations. Approximately one-fourth of those with positive
FDG-PET required further investigation in addition to the
examinations included in the screening program. Detailed
information will be described elsewhere.
Upper gastrointestinal endoscopy
All subjects were administered a 100ml solution containing 1g of
Pronase and 1g of sodium bicarbonate to remove mucus and
bubbles on the gastric mucosa before examination. The antiper-
istaltic (20mg of scopolamine butylbromide or 1mg of glucagon)
and sedative (17.5–35mg of pethidine hydrochloride or 2–10mg
of midazolam) agents were injected intravenously except when
they were contraindicated. We used standard commercial video
endoscopic equipment (GIF TYPE H-260 or Q260; Olympus Co.,
Tokyo, Japan). Endoscopic images were obtained and recorded in
a standardised pattern, which covered the entire gastric mucosa in
about 50 shots. We added chromoendoscopy with 0.2% solution
of indigo-carmine in all subjects after conventional observation.
All lesions that appeared potentially malignant were biopsied for
histopathological examination. The location, description of
lesions, and diagnosis were recorded just after the gastrointestinal
endoscopy. Size of cancer lesions was measured on the surgically
or endoscopically resected specimen. Endoscopic images were
reviewed primarily on the same day by three endoscopists (HS,
YK, and TK) to determine whether there were any lesions
overlooked during endoscopy. If any suspicious findings were
suggested to have been overlooked, the screenees were recom-
mended to undergo an additional endoscopy.
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The final pathological diagnosis was confirmed from specimens
resected surgically or endoscopically. The depth of cancer invasion
was recorded according to the TNM clinical classification (Sobin
and Wittekind, 1997). Two pathologists interpreted the histo-
pathologic features and when there was a disagreement, a senior
pathologist reviewed the features to resolve the disagreement.
Statistical analyses
The Student’s t-test was used to assess the difference in the mean
age between gastric cancer subjects and those without gastric
cancer or between male and female subjects. Statistical significance
for comparison of items other than age between subjects with
gastric cancer and subjects without gastric cancer was assessed by
w
2 test. The difference in SUV between true positives and false
positives was also analysed by the Student’s t-test. P-values o0.05
were considered statistically significant and 95% confidence
intervals (CIs) were calculated based on a binominal distribution.
RESULTS
The characteristics of the subjects enrolled in the study are shown
in Table 1. Among 2861 subjects enrolled in the study, gastric
cancers were detected by gastrointestinal endoscopy in 20 subjects,
including 18 men and 2 women. The mean age of all subjects was
59.8 years old, and there was no statistically significant difference
between subjects with gastric cancer and subjects without gastric
cancer. Males were older than females both among subjects with
gastric cancer and subjects without gastric cancer. The proportion
of males to females was significantly higher for subjects with
gastric cancer than for subjects without gastric cancer (Table 1).
AB
CD
Figure 1 Assessment of FDG-PET findings. (A) PET scan demonstrates spotty or focal accumulation that is stronger than the uptake in the liver (arrow).
(B) PET scan demonstrates focal accumulation in the area of the lower stomach (arrow). (C) PET scan demonstrates no definite accumulation of FDG in the
stomach. (D) PET scan demonstrates diffuse accumulation (normal physiological accumulation) of FDG in the stomach (arrow).
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history of gastric or any other cancer, or of previous examinations
between subjects with gastric cancer and subjects without gastric
cancer (Table 1).
Detailed clinical features of gastric cancers detected by
endoscopy are shown in the bottom of Table 1. Histopathologi-
cally, about half of the cancers were well or moderately
differentiated adenocarcinoma. Of the 20 gastric cancers, 18 were
of T1 stage (Table 2), among which cancer invasion into the gastric
wall was confined to the mucosa in 12 subjects, and to the
submucosa in six subjects. Only two subjects among 20 cases with
gastric cancer showed positive results with PET. The first patient
had T4 cancer (Borrmann type 2, poorly differentiated adenocar-
cinoma), and the FDG-PET showed strong and focal accumulation
in the area of the upper gastric body as ‘positive pattern 1’. The
second patient had T1 cancer (a superficial depressed type, signet
ring cell carcinoma), and the FDG-PET showed stronger accumu-
lation in the area of the lower gastric body, which was clearly
judged as ‘positive pattern 2’.
The overall sensitivity, specificity, and positive predictive values
were 10.0% (95% CI: 1.2–31.7%), 99.2% (95% CI: 98.8–99.5%),
and 8.3% (95% CI: 1.0–27.0%), respectively, and the negative
predictive value was 99.4% (95% CI: 99.0–99.6%) (Table 3). There
were 22 subjects with positive FDG- PET accumulation in addition
to two cases of gastric cancer. These 22 subjects had no other
neoplastic lesions detected in the colon, nor in the other
abdominal organs by colonoscopy and ultrasound sonography.
We compared the SUV between FDG-PET true positives (two
subjects) and FDG-PET false positives (22 subjects). The
mean±s.d. of the SUVs was 4.9±1.46 in true positives and
4.5±0.96 in false positives, and there was no significant difference
between them.
Table 1 Characteristics of subjects enrolled in this study
Variables
Subjects with gastric
cancers (n¼20)
Subjects without gastric
cancers (n¼2841) P-value
§
Age (mean±s.d.) (year)
Overall 63.1±5.1 59.8±7.0 0.0368
Male 64.1±4.1 61.1±6.0 0.0330
Female 53.5±0.7 58.2±7.7 0.3919
Sex
Male/female 18/2 1582/1259 0.0043
Family history of gastric cancer
Within second degree family 6 591 0.4638
Within first degree family 5 470 0.4769
Family history of any cancer
Within second degree family 14 1842 0.8048
Within first degree family 11 1511 40.9999
History of gastric examinations
a 11 1578 40.9999
Barium meal X-ray examination 8 1051 0.9640
Gastrointestinal endoscopy 4 780 0.6217
Characteristics of gastric cancer
Location
b (U area/M area/L area) 4/5/11
Size
c (–10mm/11–20mm/21mm–) 6/7/7
Histological type
Differentiated adenocarcinoma (Well/Mod) 11(11/0)
Undifferentiated adenocarcinoma (Por/Sig/
Mixed (Sig/Por))
9(1/4/4)
Mod¼moderately differentiated adenocarcinoma; Por¼poorly differentiated adenocarcinoma; Sig¼signet ring cell carcinoma; Well¼well-differentiated adenocarcinoma.
yStatistical significance for comparison of each item between subjects with gastric cancer and without gastric cancer.
aProportion of subjects who had undergone stomach
examination as a screening test or diagnostic test with X-ray examination and/or gastrointestinal endoscopy within 1 year before the screening endoscopy in this study.
bLocation
of a lesion is based on the ‘Japanese Classification of Gastric Carcinoma’ (The 13th Edition, 1999) by Japanese Gastric Cancer Association.
cMaximum diameter of cancer lesions.
Table 2 FDG-PET results according to depth of cancer invasion
Depth of invasion
a
T1 T2 T3 T4
FDG-PET positive n¼210 0 1
FDG-PET negative n¼18 17 1 0 0
Total n¼20 18 1 0 1
FDG-PET denotes
18F-2-deoxy-2-fluoro-glucose positron emission tomography. T1:
tumour invades lamina propria or submucosa. T2: tumour invades muscularis propria
or subserosa. T3: tumour penetrates serosa (visceral peritoneum) without invasion of
adjacent structures. T4: tumour invades adjacent structures.
aThe depths of cancer
invasion were based on the TNM classification.
Table 3 Sensitivity and specificity of FDG-PET for gastric cancer
Subjects with gastric
cancers (n¼20)
Subjects without gastric
cancers (n¼2841)
FDG-PET positive
n¼24
22 2
FDG-PET negative
n¼2837
18 2819
CI¼confidence interval. Sensitivity (95% CI)¼2/20¼10% (1.2–31.7%). Specificity
(95% CI)¼2819/2841¼99.2% (98.8–99.5%). Positive predictive value¼2/24¼8.3%
(1.0–27.0%). Negative predictive value¼2819/2837¼99.4% (99.0–99.6%).
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We have shown that the sensitivity of FDG-PET for gastric cancer
is as low as 10% in this study. Although the sensitivity of FDG-PET
for gastric cancer has been reported in some studies to range from
60 to 94% (Yeung et al, 1998; De Potter et al, 2002; Stahl et al, 2003;
Yoshioka et al, 2003; Mochiki et al, 2004; Chen et al, 2005; Yun
et al, 2005), the subjects used in those reports were primarily
clinically diagnosed, preoperative, advanced cancer, or recurrent
cancer cases, and thus the sensitivity values calculated in those
studies may not represent screening sensitivity. Screening
sensitivity can only be measured in an asymptomatic population,
preferably by performing diagnostic examination such as endo-
scopy on all subjects in order to identify cancer subjects in the
population. There have been no other studies that have evaluated
the sensitivity of FDG-PET for gastric cancer in an asymptomatic
population based on the findings of endoscopy as the gold
standard.
There are a few issues to be addressed, which might have
influenced the sensitivity calculated in this study. Firstly, our case
series of screen-detected cancers consists largely of cancers in the
early stages, and the proportion of more advanced cancers was
very small (2 of 20) (Table 2). Our previous report showed a little
higher detection rate of gastric cancer in men than expected, which
suggested possible overdiagnosis among screen-detected cancers
(Hamashima et al, 2006). The high proportion of early cancers,
including those of overdiagnosis among screen-detected
cancers, could be a reason for our low sensitivity. There is one
study from Japan in which the sensitivity of FDG-PET for early
gastric cancer could be calculated, although the subjects used were
clinically diagnosed cancers. Mochiki et al (2004) reported that the
sensitivity was 40% in gastric cancers of T1 stage subsequently
treated surgically. Although detailed information on the depth of
cancer invasion was not available in that paper, the case series in
their report was estimated to be of a more invasive nature than
those in the present study in terms of depth of invasion. Because
the indication for surgical resection of gastric cancer in terms of
depth of cancer invasion is submucosal or deeper invasion in
Japan, the subjects with T1 stage cancers would have had
submucosal invasion in their study. In the present study, 12 out
of 18 T1 cancers were intramucosal cancer, which did not
necessarily require surgery. This difference might explain the
difference in sensitivity for early cancer detection between the two
studies. However, even when intramucosal cancers were excluded
from the calculation, the sensitivity was only 12.5% (one positive out
of eight). Secondly, in our study, we performed chromoendoscopy
on all screenees, which might have enhanced the ability to detect
small cancer lesions. Thirty percent of cancer lesions were 10mm or
less in diameter (Table 1). In any case, the calculated sensitivity in
this study might be underestimated due to potential overdiagnosis
relevant to screen-detected cancer as mentioned above.
The FDG-PET procedure employed in this study is based on the
standard method used in clinical practice, except for the criteria
for assessment of cancer. PET findings were assessed according to
the criteria, which we defined, due to lack of established criteria.
The main difficulty in FDG-PET diagnosis of stomach cancer is
physiological uptake in the stomach (Cook et al, 1996; Gordon
et al, 1997; Shreve et al, 1999; Koga et al, 2003), but there was no
cancer subject in whom we had difficulty in differentiating
physiological uptake from cancer lesions. Nevertheless, it is
possible that there were tiny cancers overlooked due to significant
FDG background uptake. As physiological uptake is more
significant in the oral end of the stomach than in the anal end,
screen-detected cancers with FDG-PET might be biased towards
cancers in the anal end of the stomach.
In this study, there were 22 subjects with false-positive PET.
There remains the possibility that upper gastrointestinal endo-
scopy had overlooked tiny lesions rather than that they were false
positives. However, endoscopic images recorded in as many as
approximately 50 shots were reviewed just after endoscopy to
check for overlooked lesions. Therefore, it is unlikely that
overlooked lesions were a main reason for such a low sensitivity.
It might be necessary to compare FDG-PET findings with those
of existing examinations, such as barium meal and gastrointestinal
endoscopy in terms of efficacy, cost, convenience, and radiation
dose. Efficacy has been evaluated only for barium meal examina-
tions in Japan by case–control studies (Oshima et al, 1986; Fukao
et al, 1995; Mizoue et al, 2003).
18F-2-deoxy-2-fluoro-glucose
Positron Emission Tomography is more expensive than the other
two procedures (85000 Japanese yen or 772 US$ for FDG-PET,
12680 yen or 115 US$ for endoscopy in our screening program,
and about 82 US$ for barium meal examination). There is much
less inconvenience for screenees with FDG-PET than is seen after
endoscopy or barium meal examination, which are often
accompanied by discomfort during examination, side effects of
antispasmodic agents, or constipation after examination. With
regard to radiation dose, the average dose at our facility during the
current study was 3.2mSv for FDG-PET and 4.4mSv for CT, which
are similar to prior reports of barium meal examination that
ranged from 3.0 to 9.3mSv (Broadhead et al, 1995; Geleijns et al,
1998), although the radiation dose of screening fluorography in
Japan would be lower than barium meal examination as a
diagnostic test (Kato et al, 1999).
This study did not evaluate the efficacy of FDG-PET screening
for gastric cancer. Moreover, in this study, the sensitivity for more
advanced cancers, which would be less likely to be affected by
overdiagnosis, could not be measured due to an insufficient
number of such cancers among screen-detected cancers. The
sensitivity calculated here might thus be an underestimate of that
for all gastric cancers. However, in conclusion, it was clearly
demonstrated in this study that FDG-PET is poorly sensitive for
the detection of gastric cancer in the early stages.
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